FilingSEC EDGAR8-K
REGENXBIO Settles Patent Litigation with Sarepta for $39 Million
· SEC accepted
StageSettlement reached
Filing content
REGENXBIO entered into a settlement agreement with Sarepta Therapeutics and Catalent to resolve patent litigation, receiving a $39 million payment within 10 days.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…